Q2 FY2026 · ended Jun 30, 2026 · Revenue $250,000 · Filed Aug 13, 2026
Oncotelic Therapeutics, Inc. (OTLC) files with the SEC under industry code 2834, Pharmaceutical Preparations. In Q2 of fiscal 2026, the quarter ended Jun 30, 2026, it reported revenue of $250,000 and net income of $388,147.
Revenue
$250,000
Net income
$388,147
+39.7% vs year-ago quarter
Operating cash flow
$-92,197
+26.9% vs year-ago quarter
Free cash flow
—
EPS
$0.00
Dividend per share
None
Shares outstanding
457.51M
+5.2% vs year-ago quarter
Net cash
$-2.33M
Q4 FY2024
Operating margin
-337.4%
Q2 FY2026
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- OTLC (OTC)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Aguora Hills, CA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 908259
- Former names
- MATEON THERAPEUTICS INC (until Mar 26, 2021); OXIGENE INC (until Jun 3, 2016)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q2 FY2026 Jun 30, 2026 |
Q1 FY2026 Mar 31, 2026 |
Q4 FY2025 Dec 31, 2025 |
Q3 FY2025 Sep 30, 2025 |
Q2 FY2025 Jun 30, 2025 |
|---|---|---|---|---|---|
| Revenue | $250,000 | — | — | — | — |
| Operating income | -$843,565 | -$1.9M | -$2.5M | -$490,973 | -$65,969 |
| Net income | $388,147 | -$2.2M | $250.4M | -$1.0M | $277,856 |
| Diluted EPS | $0.00 | $0.00 | — | — | $0.00 |
| Operating cash flow | -$92,197 | -$342,243 | -$783,017 | -$307,022 | -$126,151 |
| Total assets | $394.8M | $394.0M | $393.1M | $28.2M | $26.7M |
| Total liabilities | $131.3M | $131.7M | $131.4M | $20.1M | $19.3M |
| Stockholders' equity | $264.6M | $263.3M | $262.8M | $9.1M | $8.3M |
| Cash and investments | $186,014 | $63,614 | $88,857 | — | — |
| Total debt | — | — | — | — | $2.7M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Other events
|
Oct 26, 2026 | Oct 26, 2026 |
| 8-K |
Current report
Other events
|
Oct 13, 2026 | Oct 7, 2026 |
| 10-Q | Quarterly report | Aug 13, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Material agreement, New debt, Unregistered share sale
|
Aug 4, 2026 | Aug 3, 2026 |
| 8-K |
Current report
Other events
|
Jul 14, 2026 | Jul 13, 2026 |
| 8-K |
Current report
Unregistered share sale, Officer or director change
|
Jul 14, 2026 | Jul 10, 2026 |
All 1007 Oncotelic Therapeutics, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.